[Characterization of antirubella vaccine in an epidemiological trial].
The work was aimed at the evaluation of the antigenic activity and reactogenicity of antirubella vaccine, manufactured by the Serum Institute of India, on the basis of the active observation of 373 children. Vaccinal reactions were registered in 8.8% of the vaccinees. Seroconversion after the injection of the vaccine was 100%. The results of the epidemiological trial demonstrated that the Indian antirubella vaccine was faintly reactogenic and had high antigenic activity.
Popov
V F
VF
Iunasova
T N
TN
Gaĭderova
L A
LA
Aksenov
L A
LA
Averina
O B
OB
Shitikova
O Iu
OIu
D000293:Adolescent; D000914:Antibodies, Viral / Q000097:blood; D000918:Antibody Specificity; D002648:Child; D002675:Child, Preschool; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007223:Infant; D012409:Rubella / Q000097:blood / Q000517:prevention & control*; D012411:Rubella Vaccine / Q000008:administration & dosage* / Q000009:adverse effects; D012412:Rubella virus / Q000276:immunology*; D012426:Russia; D014611:Vaccination
D000914:Antibodies, Viral; D012411:Rubella Vaccine